"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Editorial
peer-reviewed

Addressing Hazards from Unscheduled Novel Psychoactive Substances as Research Chemicals: The Case of U-50488



Abstract

Increased experimentation with easily accessible synthetic opioids is posing a hazard to the public. We discuss one such synthetic opioid, U-50488. Much is unknown about U-50488; however, due to its structural similarity to U-47700, there is possible risk associated with its use. Curtailing the use of synthetic opioids such as U-50488 will require a concerted effort targeting multiple problems.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Editorial
peer-reviewed

Addressing Hazards from Unscheduled Novel Psychoactive Substances as Research Chemicals: The Case of U-50488


Author Information

Zubair M. Amin

Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific

Kerry Anne Rambaran

Department of Clinical Sciences, Keck Graduate Institute

Steven W. Fleming

Reference Health Laboratories, Gulfstream Diagnostics

Kevin Cho

Reference Health Laboratories, Gulfstream Diagnostics

Liza Chacko

Reference Health Laboratories, Gulfstream Diagnostics

Saeed K. Alzghari Corresponding Author

Gulfstream Genomics, Gulfstream Diagnostics


Ethics Statement and Conflict of Interest Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Saeed Alzghari, Steven Fleming, Kevin Cho, and Liza Chacko declare(s) employment from Gulfstream Diagnostics. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.


Editorial
peer-reviewed

Addressing Hazards from Unscheduled Novel Psychoactive Substances as Research Chemicals: The Case of U-50488


Figures etc.

Share
Editorial
peer-reviewed

Addressing Hazards from Unscheduled Novel Psychoactive Substances as Research Chemicals: The Case of U-50488

Zubair M. Amin">Zubair M. Amin, Kerry Anne Rambaran">Kerry Anne Rambaran, Steven W. Fleming">Steven W. Fleming, Kevin Cho">Kevin Cho, Liza Chacko">Liza Chacko, Saeed K. Alzghari">Saeed K. Alzghari

  • Author Information
    Zubair M. Amin

    Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific

    Kerry Anne Rambaran

    Department of Clinical Sciences, Keck Graduate Institute

    Steven W. Fleming

    Reference Health Laboratories, Gulfstream Diagnostics

    Kevin Cho

    Reference Health Laboratories, Gulfstream Diagnostics

    Liza Chacko

    Reference Health Laboratories, Gulfstream Diagnostics

    Saeed K. Alzghari Corresponding Author

    Gulfstream Genomics, Gulfstream Diagnostics


    Ethics Statement and Conflict of Interest Disclosures

    Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Saeed Alzghari, Steven Fleming, Kevin Cho, and Liza Chacko declare(s) employment from Gulfstream Diagnostics. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

    Acknowledgements


    Article Information

    Published: December 06, 2017

    DOI

    10.7759/cureus.1914

    Cite this article as:

    Amin Z M, Rambaran K, Fleming S W, et al. (December 06, 2017) Addressing Hazards from Unscheduled Novel Psychoactive Substances as Research Chemicals: The Case of U-50488. Cureus 9(12): e1914. doi:10.7759/cureus.1914

    Publication history

    Received by Cureus: November 11, 2017
    Peer review began: November 14, 2017
    Peer review concluded: December 04, 2017
    Published: December 06, 2017

    Copyright

    © Copyright 2017
    Amin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Increased experimentation with easily accessible synthetic opioids is posing a hazard to the public. We discuss one such synthetic opioid, U-50488. Much is unknown about U-50488; however, due to its structural similarity to U-47700, there is possible risk associated with its use. Curtailing the use of synthetic opioids such as U-50488 will require a concerted effort targeting multiple problems.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Zubair M. Amin, Pharmacy Student

Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific

Kerry Anne Rambaran, Assistant Professor

Department of Clinical Sciences, Keck Graduate Institute

Steven W. Fleming, M.Sc.

Reference Health Laboratories, Gulfstream Diagnostics

Kevin Cho

Reference Health Laboratories, Gulfstream Diagnostics

Liza Chacko

Reference Health Laboratories, Gulfstream Diagnostics

Saeed K. Alzghari, M.S., M.B.A. (HOM), Pharm.D., BCPS

Gulfstream Genomics, Gulfstream Diagnostics

For correspondence:
salzghari@gulfdiagnostics.com

Zubair M. Amin, Pharmacy Student

Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific

Kerry Anne Rambaran, Assistant Professor

Department of Clinical Sciences, Keck Graduate Institute

Steven W. Fleming, M.Sc.

Reference Health Laboratories, Gulfstream Diagnostics

Kevin Cho

Reference Health Laboratories, Gulfstream Diagnostics

Liza Chacko

Reference Health Laboratories, Gulfstream Diagnostics

Saeed K. Alzghari, M.S., M.B.A. (HOM), Pharm.D., BCPS

Gulfstream Genomics, Gulfstream Diagnostics

For correspondence:
salzghari@gulfdiagnostics.com